cefteram pivoxil

structure given in first source

Also Known As:

Ro 19-5248; Ro-19-5248; T 2588; T-2588; Tomiron; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((5-methyl-2H-tetrazol-2-yl)methyl)-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R-(6alpha,7beta(Z)))-

Networked: 27 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Di, Bin: 1 article (04/2008)
2.	Fan, Hongwei: 1 article (04/2008)
3.	Hu, Qin: 1 article (04/2008)
4.	Li, Jian Hua: 1 article (04/2008)
5.	Wang, Guang Ji: 1 article (04/2008)
6.	Wu, Chun Yong: 1 article (04/2008)
7.	Xiao, DaWei: 1 article (04/2008)
8.	Zhu, Yubing: 1 article (04/2008)
9.	Zou, Jianjun: 1 article (04/2008)
10.	Mikamo, Hiroshige: 1 article (08/2005)

Related Diseases

1.	Infections 10/01/1986 - "In conclusion, T-2588 can be to be expected sufficiently clinically effective against gonorrheal infections, including PPNG, at a daily dose of 600 mg t.i.d. " 08/01/1989 - "[Clinical studies of cefteram pivoxil in pediatric infection]." 10/01/1986 - "[Epidemiological and therapeutic studies on gonorrheal infections--clinical efficacy of T-2588. " 08/01/1989 - "Cefteram pivoxil (CFTM-PI), in fine granules, was studied in pediatric infections and the results obtained are summarized below. " 08/01/1989 - "[Clinical evaluation of cefteram pivoxil fine granules in pediatric infections]."
2.	Pneumonia (Pneumonitis) 02/01/1990 - "The usefulness of cefteram pivoxil (CFTM-PI) was evaluated in 99 cases with respiratory tract infections: 32 cases with acute bronchitis, 51 cases with infectious exacerbations of chronic respiratory diseases and 16 cases with pneumonia. " 11/01/1986 - "T-2588 was used on 55 patients with respiratory tract infections and 44 cases were evaluated; 23 patients with pneumonia, 12 patients with acute bronchitis, 2 patients with chronic bronchitis, 1 patient with diffuse panbronchiolitis and 6 patients with bronchiectasis with infection. " 01/01/1998 - "The efficacy of CS-834, a novel oral carbapenem, was assessed by using a murine model of pneumonia caused by penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and was compared with those of oral cephems, i.e., cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil. "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/1990 - "[Clinical studies on cefteram pivoxil in the treatment of respiratory infections]." 11/01/2004 - "Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method." 02/01/1990 - "[Clinical evaluation of cefteram pivoxil in respiratory tract infections]." 11/01/1986 - "Therefore, T-2588 is a useful drug and its effects are promising in clinical management of respiratory tract infections." 11/01/1986 - "[Evaluation of T-2588 in the treatment of respiratory tract infection]."
4.	Soft Tissue Infections 11/01/1989 - "[The studies on clinical efficacy of Tomiron in the surgical patients: skin and soft tissue infection]." 11/01/1989 - "These results indicate that Tomiron is a useful oral antimicrobial agent in the treatment and prophylaxis of surgical infection, mainly skin and soft tissue infection."
5.	Hypotension (Low Blood Pressure) 04/01/1986 - "On the central nervous system, T-2588 did not show any effects at oral doses of 500-2,000 mg/kg and T-2525 produced only a slight elevation of body temperature in rabbits without any other effects at an intravenous dose of 500 mg/kg. On the respiratory and cardiovascular systems, T-2525 caused a slight hypotension and increased both respiratory rate and femoral blood flow, but no changes were observed in heart rate and electrocardiogram in dogs at an intravenous dose of 500 mg/kg. The T-2525 exerted no significant influence on blood pressure response to isoproterenol, acetylcholine or histamine, but showed a slight tendency to decrease pressor response to adrenaline in dogs at intravenous doses of 100-500 mg/kg. For the renal function in rats, T-2588 had no effects on urine volume, electrolytes and PSP excretion at oral doses of 500-2,000 mg/kg. Intravenous administration of T-2525 caused an increase of sodium excretion at 500 mg/kg and dose-dependent increases of PSP excretion at 20-500 mg/kg. Hematological studies revealed that both T-2588 at oral doses of 500-2,000 mg/kg and T-2525 at intravenous doses of 100-500 mg/kg had no effects on bleeding time in mice, blood coagulation and platelet aggregation in rats. "

Related Drugs and Biologics

1.	Cefdinir (Omnicef)
2.	Cefpodoxime Proxetil (Vantin)
3.	CS 834
4.	cefditoren pivoxil (Spectracef)
5.	Carbapenems (Carbapenem Antibiotics)
6.	Penicillins (Penicillin)
7.	Sodium
8.	Isoproterenol (Isoprenaline)
9.	Histamine (Histamine Dihydrochloride)
10.	Epinephrine (Adrenaline)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)